← back to search

Zhigang Ma

Harbin Medical University · CN
Area of research
Nutrition and Dietetics · Oncology
Research interest
Research interests include Medicine, Internal medicine, Colorectal cancer, Oncology, Clinical endpoint, and Gastroenterology.
h-index
citations
543
works
17
NIH funding
primary concept
email

Recent publications

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
Nature Communications 2025cited by 28position: middledoi
Comparing Immunotherapy Versus Chemotherapy Alone as Second-Line Therapy for Malignant Tumors of the Biliary Tract: A Retrospective Study
Clinical Medicine Insights Oncology 2025cited by 2position: middledoi
Lipopolysaccharide-induced DNA damage response activates DNA-PKcs to drive actin cytoskeleton disruption and cardiac microvascular dysfunction in endotoxemia
Theranostics 2025cited by 2position: middledoi
Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma
The Oncologist 2024cited by 1position: middledoi
Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis
The Oncologist 2023cited by 19position: middledoi
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Clinical Cancer Research 2022cited by 55position: middledoi
Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Journal of Clinical Oncology 2022cited by 5position: middledoi
SO-17 A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
Annals of Oncology 2022cited by 4position: middledoi
Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
Frontiers in Cell and Developmental Biology 2021cited by 64position: middledoi
Camrelizumab combined with ablation and chemotherapy for pancreatic cancer with liver metastases: A single-arm, phase II, prospective clinical study.
Journal of Clinical Oncology 2021cited by 2position: middledoi
Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma
Bioscience Reports 2020cited by 40position: middledoi
Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes
British Journal of Cancer 2020cited by 29position: middledoi
987P A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC)
Annals of Oncology 2020cited by 12position: middledoi
Overexpression of Arginase-1 is an indicator of poor prognosis in patients with colorectal cancer
Pathology - Research and Practice 2019cited by 66position: firstdoi
Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway
Biomedicine & Pharmacotherapy 2018cited by 47position: middledoi
LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway
Oncology Reports 2014cited by 137position: middledoi
ETV1 induces epithelial to mesenchymal transition in human gastric cancer cells through the upregulation of Snail expression
Oncology Reports 2013cited by 30position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yanqiao Zhang · Zhejiang Provincial People's Hospital6 papers (2014–2025)Changjie Lou · Harbin Medical University5 papers (2018–2024)Chao Liu · Harbin Medical University4 papers (2019–2021)Xiaona Fan · Harbin Medical University3 papers (2020–2024)Haibo Lu · The University of Texas Southwestern Medical Center2 papers (2018–2024)Qi Zhao · Academy of Medical Sciences2 papers (2014–2019)Hengzhen Li · Harbin Medical University2 papers (2021–2024)Y. Zhang · Harbin Medical University2 papers (2020–2022)Zheng‐Xiang Li · Shanxi Medical University2 papers (2014–2021)Chunhui Zhang · Nantong University2 papers (2020–2025)Zhiwei Li · Nanchang University2 papers (2020–2021)Zhiwei Li · Ningbo University2 papers (2013–2021)Ma Qian · National University of Singapore2 papers (2023–2025)Guangyu Wang · Shandong University2 papers (2021–2024)Guangyu Wang · Tongji University2 papers (2014–2021)Qingwei Li · South China Agricultural University2 papers (2021–2021)Jiebing Tang · Harbin Medical University2 papers (2013–2025)Yanqiao Zhang · Harbin Medical University2 papers (2018–2020)Ci Zhao · Harbin Medical University2 papers (2014–2019)Xin Guan · Harbin Medical University2 papers (2020–2021)